Since the approval of anti-CTLA-4 for the treatment of metastatic melanoma in 2011, various T cell modulators, immune check point inhibitors (ICIs), CAR-T cells, TIL therapy, oncolytic viruses, and intra-tumor immune stimulators have emerged as promising therapeutics (1, 2). Here, CTLA4 is linked to neoplasm.